Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.61 |
| ▸ | EGLN3 | Q9H6Z9 | 5/20 | 0.61 |
| ▸ | P4HTM | Q9NXG6 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17755644 | 0.93 | — | — | |
| SCHEMBL9104978 | 0.93 | GPBAR1 (0.60) | — | |
| SCHEMBL9888552 | 0.93 | — | — | |
| SCHEMBL18525879 | 0.93 | GPBAR1 (0.60) | — | |
| SCHEMBL12698045 | 0.93 | GPBAR1 (0.60) | — | |
| SCHEMBL9110443 | 0.93 | GPBAR1 (0.60) | — | |
| SCHEMBL9110039 | 0.93 | GPBAR1 (0.60) | — | |
| SCHEMBL17756310 | 0.92 | — | — | |
| SCHEMBL9108197 | 0.92 | — | — | |
| SCHEMBL20026478 | 0.92 | EGLN2 (0.51) | EGLN2EGLN1EGLN3P4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221208-B2 | Methods of producing an HIV maturation inhibitor | ViiV Healthcare UK (No.4) Limited (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20180094019-A1 | CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2018-04-05 | — | — | US | disclosed |
| US-20180072691-A1 | METHODS OF PRODUCING AN HIV MATURATION INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221208-B2 | Methods of producing an HIV maturation inhibitor | TMBIM6, MCL1, FURIN | EGLN2 1424/4885EGLN1 729/4885EGLN3 2036/4885 |
| US-20180072691-A1 | METHODS OF PRODUCING AN HIV MATURATION INHIBITOR | TMBIM6, MCL1, FURIN | EGLN2 1424/4885EGLN1 729/4885EGLN3 2036/4885 |
| US-20180094019-A1 | CRYSTALLINE FORMS OF MODIFIED TRITERPENOID HYDROCHLORIDE SALTS WITH HIV MATURATION INHIBITOR ACTIVITY | CYP4F11, GTF3C4, CYP4A11 | EGLN2 4292/4885EGLN1 4319/4885EGLN3 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.